Cixutumumab
Cixutumumab is a biological therapy with 27 clinical trials. Currently 1 active trials ongoing. Historical success rate of 96.2%.
Success Metrics
Based on 25 completed trials
Phase Distribution
Phase Distribution
12
Early Stage
15
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
96.2%
25 of 26 finished
3.8%
1 ended early
1
trials recruiting
27
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
Clinical Trials (27)
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
A Study in Non-Small Cell Lung Cancer
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
A Study of IMC-A12 in Advanced Solid Tumors
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 27